239 related articles for article (PubMed ID: 30150234)
1. Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy.
Douros A; Filion KB; Yin H; Yu OH; Etminan M; Udell JA; Azoulay L
Diabetes Care; 2018 Nov; 41(11):2330-2338. PubMed ID: 30150234
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies.
Zheng D; Li N; Hou R; Zhang X; Wu L; Sundquist J; Sundquist K; Ji J
BMC Med; 2023 Feb; 21(1):40. PubMed ID: 36737746
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors associated with the occurrence of nausea and vomiting in type 2 diabetes patients treated with glucagon-like peptide-1 receptor agonists.
Shiomi M; Takada T; Tanaka Y; Yajima K; Isomoto A; Sakamoto M; Otori K
J Diabetes Investig; 2019 Mar; 10(2):408-417. PubMed ID: 30033675
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.
Avgerinos I; Karagiannis T; Malandris K; Liakos A; Mainou M; Bekiari E; Matthews DR; Tsapas A
Diabetes Obes Metab; 2019 Jan; 21(1):188-193. PubMed ID: 30058208
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
6. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
7. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
8. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
9. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study.
Pradhan R; Yu OHY; Platt RW; Azoulay L
Diabet Med; 2024 Apr; 41(4):e15248. PubMed ID: 37876318
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials.
Kapoor I; Sarvepalli SM; D'Alessio D; Grewal DS; Hadziahmetovic M
Surv Ophthalmol; 2023; 68(6):1071-1083. PubMed ID: 37454782
[TBL] [Abstract][Full Text] [Related]
12. Weight-lowering Effects of Glucagon-like Peptide-1 Receptor Agonists and Detection of Breast Cancer Among Obese Women with Diabetes.
Santella C; Yin H; Hicks BM; Yu OHY; Bouganim N; Azoulay L
Epidemiology; 2020 Jul; 31(4):559-566. PubMed ID: 32282437
[TBL] [Abstract][Full Text] [Related]
13. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
14. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Igweokpala S; Sule NO; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2024 Feb; 26(2):721-731. PubMed ID: 38031234
[TBL] [Abstract][Full Text] [Related]
16. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
17. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
18. Association between Glucose-lowering Treatments and Risk of Diabetic Retinopathy in People with Type 2 Diabetes: A Nationwide Cohort Study.
Hasselstrøm Jensen J; Vestergaard P; Hasselstrøm Jensen M
Curr Drug Saf; 2024; 19(2):236-243. PubMed ID: 37078347
[TBL] [Abstract][Full Text] [Related]
19. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
